{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:09:56Z","timestamp":1789160996282,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81660027"],"award-info":[{"award-number":["81660027"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960031"],"award-info":[{"award-number":["81960031"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovative Talents Team Program of Guizhou Province","award":["No.2019-5610"],"award-info":[{"award-number":["No.2019-5610"]}]},{"name":"the Science and Technology Project of Guizhou Province","award":["No.2018-5779-70"],"award-info":[{"award-number":["No.2018-5779-70"]}]},{"name":"the Science and Technology Project of Guizhou Province","award":["19NSP079"],"award-info":[{"award-number":["19NSP079"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n \n IL-35 is a potent immunosuppressive and anti-inflammatory cytokine, consisting of a p35 subunit and an Epstein\u2013Barr virus\u2013induced gene 3 (EBI3) subunit, which suppresses CD4\n +<\/jats:sup>\n effector T cell proliferation and promotes regulatory T cell (Treg) expansion. However, the effects of IL-35 on regulatory B cells (Bregs) in ankylosing spondylitis (AS) have not been explored. The present study aimed (i) to measure serum IL-35 levels and the percentages of Bregs in the peripheral blood of patients with AS and (ii) to explore their relationships in the pathogenesis of AS.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A total of 77 patients with AS (AS group), including 47 inactive AS and 30 active AS cases, and 59 healthy controls (HCs) were enrolled into this study. The serum levels of IL-35 and IL-10 were detected by ELISA, and the mRNA levels of p35 and EBI3 were measured by RT\u2013qPCR. The percentages of CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD38\n hi<\/jats:sup>\n and CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD27\n +<\/jats:sup>\n Bregs and IL-35 receptor (IL-12R\u03b22, IL-27R\u03b1 and gp130), IL-10, p-STAT1, p-STAT3, and p-STAT4 in CD19\n +<\/jats:sup>\n B cells were detected by flow cytometry. The correlations between IL-35 levels and percentages of Bregs were analyzed by determining Pearson\u2019s correlation coefficient. The effect of IL-35 on Bregs was determined by mix-culture of recombinant (r) IL-35 with peripheral blood mononuclear cells (PBMCs).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The serum IL-35 and IL-10 levels,\n p35<\/jats:italic>\n and\n EBI3<\/jats:italic>\n mRNA levels, and the percentages of CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD38\n hi<\/jats:sup>\n and CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD27\n +<\/jats:sup>\n Bregs were significantly lower in AS patients than those in HCs. In addition, the percentages of CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD38\n hi<\/jats:sup>\n and CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD27\n +<\/jats:sup>\n Bregs in active AS patients were significantly lower than those in inactive AS patients. The serum IL-35 levels were positively correlated with the percentages of CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD38\n hi<\/jats:sup>\n and CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD27\n +<\/jats:sup>\n Bregs in AS patients. IL-12R\u03b22 and IL-27R\u03b1, but not gp130 subunit, were expressed in CD19\n +<\/jats:sup>\n B cells in AS patients. RIL-35 could effectively promote CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD38\n hi<\/jats:sup>\n Breg expansion and IL-10 production. Meanwhile, rIL-35 also promoted the expression of IL-12R\u03b22 and IL-27R\u03b1 and the phosphorylation of STAT1 and STAT3 in CD19\n +<\/jats:sup>\n B cells.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n These results demonstrated that reduced IL-35 production may be associated with Bregs defects in AS patients. RIL-35 induced the proliferation of CD19\n +<\/jats:sup>\n CD24\n hi<\/jats:sup>\n CD38\n hi<\/jats:sup>\n Bregs and IL-10 production, suggesting that IL-35 may serve as a reference for further investigation to develop novel treatments for AS.\n <\/jats:p>\n \n \n \n \n \n \n Key Points<\/jats:bold>\n \u2022\n Our study investigated the effects of IL-35 on Bregs in AS patients.<\/jats:italic>\n \u2022\n We found the serum IL-35, IL-10 levels, and the percentages of CD19<\/jats:italic>\n +<\/jats:sup>\n CD24<\/jats:italic>\n \n hi<\/jats:italic>\n <\/jats:sup>\n CD38<\/jats:italic>\n \n hi<\/jats:italic>\n <\/jats:sup>\n and CD19<\/jats:italic>\n +<\/jats:sup>\n CD24<\/jats:italic>\n \n hi<\/jats:italic>\n <\/jats:sup>\n CD27<\/jats:italic>\n +<\/jats:sup>\n Bregs were significantly lower in AS patients.<\/jats:italic>\n \u2022\n The serum IL-35 levels were positively correlated with the percentages of CD19<\/jats:italic>\n +<\/jats:sup>\n CD24<\/jats:italic>\n \n hi<\/jats:italic>\n <\/jats:sup>\n CD38<\/jats:italic>\n \n hi<\/jats:italic>\n <\/jats:sup>\n and CD19<\/jats:italic>\n +<\/jats:sup>\n CD24<\/jats:italic>\n \n hi<\/jats:italic>\n <\/jats:sup>\n CD27<\/jats:italic>\n +<\/jats:sup>\n Bregs in AS patients.<\/jats:italic>\n \u2022\n Recombinant IL-35 could effectively promote CD19<\/jats:italic>\n +<\/jats:sup>\n CD24<\/jats:italic>\n \n hi<\/jats:italic>\n <\/jats:sup>\n CD38<\/jats:italic>\n \n hi<\/jats:italic>\n <\/jats:sup>\n Breg expansion and IL-10 production.<\/jats:italic>\n <\/jats:td>\n <\/jats:tr>\n <\/jats:tbody>\n <\/jats:table>\n <\/jats:table-wrap>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s10067-022-06137-8","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:02:40Z","timestamp":1649894560000},"page":"2403-2416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Interleukin-35 promotes Breg expansion and interleukin-10 production in CD19+ B cells in patients with ankylosing spondylitis"],"prefix":"10.1007","volume":"41","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanrong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-1428","authenticated-orcid":false,"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"issue":"9","key":"6137_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11926-013-0351-1","volume":"15","author":"G Bakland","year":"2013","unstructured":"Bakland G, Nossent HC (2013) Epidemiology of spondyloarthritis: a review. Curr Rheumatol Rep 15(9):351. https:\/\/doi.org\/10.1007\/s11926-013-0351-1","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"6137_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11926-017-0644-x","volume":"19","author":"MN Magrey","year":"2017","unstructured":"Magrey MN, Khan MA (2017) The paradox of bone formation and bone loss in ankylosing spondylitis: evolving new concepts of bone formation and future trends in management. Curr Rheumatol Rep 19(4):17. https:\/\/doi.org\/10.1007\/s11926-017-0644-x","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"6137_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2016.01171","volume":"11","author":"Z Duan","year":"2017","unstructured":"Duan Z, Gui Y, Li C, Lin J, Gober HJ, Qin J, Lin D, Wang L (2017) The immune dysfunction in ankylosing spondylitis patients. BioSci Trends 11(1):69\u201376. https:\/\/doi.org\/10.5582\/bst.2016.01171","journal-title":"BioSci Trends"},{"key":"6137_CR4","doi-asserted-by":"publisher","unstructured":"Wen JT, Zhang DH, Fang PF, Li MH, Wang RJ, Li SH (2017) Role of Th1\/Th2 cytokines in the diagnosis and prognostic evaluation of ankylosing spondylitis. Genet Mol Res 16(1). https:\/\/doi.org\/10.4238\/gmr16019322","DOI":"10.4238\/gmr16019322"},{"issue":"11","key":"6137_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1042\/CS20160069","volume":"130","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cheng LS, Wu SD, Wang SQ, Li L, She WM, Li J, Wang JY, Jiang W (2016) IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection. Clin Sci 130(11):907\u2013919. https:\/\/doi.org\/10.1042\/CS20160069","journal-title":"Clin Sci"},{"issue":"1","key":"6137_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.immuni.2009.11.009","volume":"32","author":"PA Blair","year":"2010","unstructured":"Blair PA, Nore\u00f1a LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C (2010) CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32(1):129\u2013140. https:\/\/doi.org\/10.1016\/j.immuni.2009.11.009","journal-title":"Immunity"},{"issue":"2","key":"6137_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-07-294249","volume":"117","author":"Y Iwata","year":"2011","unstructured":"Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117(2):530\u2013541. https:\/\/doi.org\/10.1182\/blood-2010-07-294249","journal-title":"Blood"},{"issue":"173","key":"6137_CR8","doi-asserted-by":"publisher","first-page":"173ra23","DOI":"10.1126\/scitranslmed.3005407","volume":"5","author":"F Flores-Borja","year":"2013","unstructured":"Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, Mauri C (2013) CD19+CD24hiCD38hi B Cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 5(173):173ra23. https:\/\/doi.org\/10.1126\/scitranslmed.3005407","journal-title":"Sci Transl Med"},{"issue":"1","key":"6137_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12969-018-0262-9","volume":"16","author":"Q Zhao","year":"2018","unstructured":"Zhao Q, Jung LK (2018) Frequency of CD19+CD24hiCD38hi regulatory B cells is decreased in peripheral blood and synovial fluid of patients with juvenile idiopathic arthritis: a preliminary study. Pediatr Rheumatol Online J 16(1):44. https:\/\/doi.org\/10.1186\/s12969-018-0262-9","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"6137_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12026-016-8877-8","volume":"65","author":"B Yang","year":"2017","unstructured":"Yang B, Tan X, Xiong X, Wu D, Zhang G, Wang M, Dong S, Liu W, Yang H, Li Q (2017) Effect of CD40\/CD40L signaling on IL-10-producing regulatory B cells in Chinese children with Henoch-Sch\u00f6nlein purpura nephritis. Immunol Res 65(3):592\u2013604. https:\/\/doi.org\/10.1007\/s12026-016-8877-8","journal-title":"Immunol Res"},{"issue":"4","key":"6137_CR11","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.3892\/etm.2017.4925","volume":"14","author":"M Yang","year":"2017","unstructured":"Yang M, Du C, Wang Y, Liu J (2017) CD19+CD24hiCD38hi regulatory B cells are associated with insulin resistance in type I Hashimoto\u2019s thyroiditis in Chinese females. Exp Ther Med 14(4):3887\u20133893. https:\/\/doi.org\/10.3892\/etm.2017.4925","journal-title":"Exp Ther Med"},{"issue":"2","key":"6137_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/art.39437","volume":"68","author":"A Mavropoulos","year":"2016","unstructured":"Mavropoulos A, Simopoulou T, Varna A, Liaskos C, Katsiari CG, Bogdanos DP, Sakkas LI (2016) Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis. Arthritis Rheumatol 68(2):494\u2013504. https:\/\/doi.org\/10.1002\/art.39437","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"6137_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.13602\/j.cnki.jcls.2015.09.7","volume":"33","author":"GH Xue","year":"2015","unstructured":"Xue GH, Hua L, Liu XF, Chen XL, Dong L, Pan J, Zhou NJ (2015) Frequencies of human regulatory B cells in PBMC in ankylosing spondylitis patients and its clinical significance. Chin J Clin Lab Sci 33(9):662\u2013667. https:\/\/doi.org\/10.13602\/j.cnki.jcls.2015.09.7","journal-title":"Chin J Clin Lab Sci"},{"issue":"2","key":"6137_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1089\/dna.2015.3046","volume":"35","author":"M Chen","year":"2016","unstructured":"Chen M, Zhang L, Ren Y, Zhang K, Yang Y, Fang Y, Yan X, Peng D, Gao C, Li S (2016) Defective function of CD24(+)CD38(+) regulatory B cells in ankylosing spondylitis. DNA Cell Biol 35(2):88\u201395. https:\/\/doi.org\/10.1089\/dna.2015.3046","journal-title":"DNA Cell Biol"},{"key":"6137_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-065X.2008.00704.x","volume":"226","author":"LW Collison","year":"2008","unstructured":"Collison LW, Vignali DA (2008) Interleukin-35: odd one out or part of the family? Immunol Rev 226:248\u2013262. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00704.x","journal-title":"Immunol Rev"},{"key":"6137_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3389\/fimmu.2020.01051","volume":"11","author":"M Kang","year":"2020","unstructured":"Kang M, Choi JK, Jittayasothorn Y, Egwuagu CE (2020) Interleukin 35-producing exosomes suppress neuroinflammation and autoimmune uveitis. Front Immunol 11:1051. https:\/\/doi.org\/10.3389\/fimmu.2020.01051","journal-title":"Front Immunol"},{"issue":"1","key":"6137_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000504197","volume":"82","author":"F Xie","year":"2020","unstructured":"Xie F, Hu Q, Cai Q, Yao R, Ouyang S (2020) IL-35 inhibited Th17 response in children with allergic rhinitis. ORL J Otorhinolaryngol Relat Spec 82(1):47\u201352. https:\/\/doi.org\/10.1159\/000504197","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"issue":"1","key":"6137_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41467-017-00838-4","volume":"8","author":"IM Dambuza","year":"2017","unstructured":"Dambuza IM, He C, Choi JK, Yu CR, Wang R, Mattapallil MJ, Wingfield PT, Caspi RR, Egwuagu CE (2017) IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease. Nat Commun 8(1):719. https:\/\/doi.org\/10.1038\/s41467-017-00838-4","journal-title":"Nat Commun"},{"issue":"6","key":"6137_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nm.3554","volume":"20","author":"RX Wang","year":"2014","unstructured":"Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, Wingfield PT, Kim SH, Egwuagu CE (2014) Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 20(6):633\u2013641. https:\/\/doi.org\/10.1038\/nm.3554","journal-title":"Nat Med"},{"issue":"7169","key":"6137_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nature06306","volume":"450","author":"LW Collison","year":"2007","unstructured":"Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169):566\u2013569. https:\/\/doi.org\/10.1038\/nature06306","journal-title":"Nature"},{"issue":"3","key":"6137_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2227","volume":"13","author":"LW Collison","year":"2012","unstructured":"Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DA (2012) The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 13(3):290\u2013299. https:\/\/doi.org\/10.1038\/ni.2227","journal-title":"Nat Immunol"},{"issue":"45","key":"6137_CR22","doi-asserted-by":"publisher","first-page":"73003","DOI":"10.18632\/oncotarget.12193","volume":"7","author":"Y Ma","year":"2016","unstructured":"Ma Y, Chen L, Xie G, Zhou Y, Yue C, Yuan XL, Zheng Y, Wang W, Deng L, Shen L (2016) Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1\/STAT3. Oncotarget 7(45):73003\u201373015. https:\/\/doi.org\/10.18632\/oncotarget.12193","journal-title":"Oncotarget"},{"issue":"4","key":"6137_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Van der Linden","year":"1984","unstructured":"Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6137_CR24","first-page":"451","volume":"21","author":"MH Cardiel","year":"2003","unstructured":"Cardiel MH, Londo\u00f1o JD, Guti\u00e9rrez E, Pacheco-Tena C, V\u00e1zquez-Mellado J, Burgos-Vargas R (2003) Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 21(4):451\u2013458","journal-title":"Clin Exp Rheumatol"},{"key":"6137_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.clim.2017.04.010","volume":"184","author":"A Mavropoulos","year":"2017","unstructured":"Mavropoulos A, Varna A, Zafiriou E, Liaskos C, Alexiou I, Roussaki-Schulze AR, Vlychou M, Katsiari C, Bogdanos DP, Sakkas LI (2017) IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFN\u03b3-producing T cells. Clin Immunol 184:33\u201341. https:\/\/doi.org\/10.1016\/j.clim.2017.04.010","journal-title":"Clin Immunol"},{"issue":"1","key":"6137_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3892\/etm.2014.2046","volume":"9","author":"C Wang","year":"2015","unstructured":"Wang C, Liao Q, Hu Y, Zhong D (2015) T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis. Exp Ther Med 9(1):250\u2013256. https:\/\/doi.org\/10.3892\/etm.2014.2046","journal-title":"Exp Ther Med"},{"key":"6137_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.biopha.2018.02.059","volume":"100","author":"MJ Fattahi","year":"2018","unstructured":"Fattahi MJ, Ahmadi H, Jafarnezhad-Ansariha F, Mortazavi-Jahromi SS, Rehm BHA, Cuzzocrea S, Matsuo H, Mirshafiey A (2018) Oral administration effects of \u03b2-D-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis. Biomed Pharmacother 100:495\u2013500. https:\/\/doi.org\/10.1016\/j.biopha.2018.02.059","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"6137_CR28","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.3892\/etm.2018.5991","volume":"15","author":"S Long","year":"2018","unstructured":"Long S, Ma L, Wang D, Shang X (2018) High frequency of circulating follicular helper T cells is correlated with B cell subtypes in patients with ankylosing spondylitis. Exp Ther Med 15(5):4578\u20134586. https:\/\/doi.org\/10.3892\/etm.2018.5991","journal-title":"Exp Ther Med"},{"issue":"2","key":"6137_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111513","volume":"383","author":"J Liu","year":"2019","unstructured":"Liu J, Chen X, Hao S, Zhao H, Pang L, Wang L, Ren H, Wang C, Mao H (2019) Human chorionic gonadotropin and IL-35 contribute to the maintenance of peripheral immune tolerance during pregnancy through mediating the generation of IL-10+ or IL-35+ Breg cells. Exp Cell Res 383(2):111513. https:\/\/doi.org\/10.1016\/j.yexcr.2019.111513","journal-title":"Exp Cell Res"},{"issue":"11","key":"6137_CR30","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/eji.200737810","volume":"37","author":"W Niedbala","year":"2007","unstructured":"Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, Mclnnes IB, Liew FY (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37(11):3021\u20133029. https:\/\/doi.org\/10.1002\/eji.200737810","journal-title":"Eur J Immunol"},{"issue":"12","key":"6137_CR31","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.4049\/jimmunol.0902739","volume":"184","author":"I Kochetkova","year":"2010","unstructured":"Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW (2010) IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 184(12):7144\u20137153. https:\/\/doi.org\/10.4049\/jimmunol.0902739","journal-title":"J Immunol"},{"issue":"5","key":"6137_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12718","volume":"88","author":"J Guo","year":"2018","unstructured":"Guo J, Gu ML, Zhang W, Liu Y, Qian C, Deng A (2018) Aberrant IL-35 levels in patients with primary Sjogren\u2019s syndrome. Scand J Immunol 88(5):e12718. https:\/\/doi.org\/10.1111\/sji.12718","journal-title":"Scand J Immunol"},{"issue":"2","key":"6137_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/MAJ.0000000000000215","volume":"348","author":"H Ouyang","year":"2014","unstructured":"Ouyang H, Shi YB, Liu ZC, Wang Z, Feng S, Kong SM, Lu Y (2014) Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus. Am J Med Sci 348(2):156\u2013161. https:\/\/doi.org\/10.1097\/MAJ.0000000000000215","journal-title":"Am J Med Sci"},{"issue":"2","key":"6137_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1515\/enr-2016-0009","volume":"50","author":"H Yilmaz","year":"2016","unstructured":"Yilmaz H, Cakmak M, Ceydilek B, Demir C, Aktas A (2016) Role of interleukin-35 as a biomarker in patients with newly diagnosed Hashimoto\u2019s thyroiditis. Endocr Regul 50(2):55\u201361. https:\/\/doi.org\/10.1515\/enr-2016-0009","journal-title":"Endocr Regul"},{"issue":"2","key":"6137_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/cei.12639","volume":"181","author":"Z Cai","year":"2015","unstructured":"Cai Z, Wong CK, Dong J, Chu M, Jiao D, Kam NW, Lam CW, Tam LS (2015) Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)\/lpr mice. Clin Exp Immunol 181(2):253\u2013266. https:\/\/doi.org\/10.1111\/cei.12639","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"6137_CR36","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/rheumatology\/keu528","volume":"54","author":"S Nakano","year":"2015","unstructured":"Nakano S, Morimoto S, Suzuki S, Tsushima H, Yamanaka K, Sekigawa I, Takasaki Y (2015) Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology (Oxford) 54(8):1498\u20131506. https:\/\/doi.org\/10.1093\/rheumatology\/keu528","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"6137_CR37","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/carcin\/bgy136","volume":"39","author":"SN Hao","year":"2018","unstructured":"Hao SN, Chen X, Wang F, Shao Q, Liu J, Zhao H, Yuan C, Ren H, Mao H (2018) Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells. Carcinogenesis 39(12):1488\u20131496. https:\/\/doi.org\/10.1093\/carcin\/bgy136","journal-title":"Carcinogenesis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06137-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T09:35:08Z","timestamp":1657877708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06137-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6137"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06137-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Guizhou Medical University Hospital (approval no. 2019030\u00a0K). All participants provided written informed consent. All procedures involving human material in this study were performed in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}